Evidence map›Paper›PMID 25692376›Full record

ArticleMolecular pharmaceutics2015

Fine-tuning vitamin E-containing telodendrimers for efficient delivery of gambogic acid in colon cancer treatment.

Wenzhe Huang, Xu Wang, Changying Shi, Dandan Guo, Gaofei Xu, Lili Wang, Alexa Bodman, Juntao Luo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
8.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2020
    Review
  7. Gambogic Acid as a Candidate for Cancer Therapy: A Review.International journal of nanomedicine · 2020
    Review
  8. Gambogic acid suppresses colon cancer cell activityExperimental and therapeutic medicine · 2019
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Natural product-based nanomedicine: recent advances and issues.International journal of nanomedicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wenzhe Huang†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
Xu Wang†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
Changying Shi†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
Dandan Guo†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
Gaofei Xu†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
Lili Wang†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
Alexa Bodman†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
Juntao Luo†Department of Pharmacology and §Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13078, United States.
SUNY Upstate Medical University · US

Funding

Size-tunable cancer nanotherapeuticsR01CA140449 · NCI · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2010 to 2014
$1.6M
Rational Design and High throughput synthesis of nanocarriers for efficient drug deliveryR21EB019607 · NIBIB · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2015 to 2016
$453k
NCI NIH HHS R01 CA140449NCI NIH HHS R01CA140449NIBIB NIH HHS R21 EB019607
6 · The paper itself

Abstract

Certain natural products such as gambogic acid (GA) exhibit potent antitumor effects. Unfortunately, administration of these natural products is limited by their poor solubility in conventional pharmaceutical solvents. In this study, a series of telodendrimers, composed of linear polyethylene glycol (PEG)-blocking-dendritic oligomer of cholic acid (CA) and vitamin E (VE), have been designed with architectures optimized for efficient delivery of GA and other natural anticancer compounds. Two of the telodendrimers with segregated CA and VE domains self-assembled into stable cylindrical and/or spherical nanoparticles (NPs) after being loaded with GA as observed under transmission electron microscopy (TEM), which correlated with the dynamic light scattering (DLS) analysis of sub-30 nm particle sizes. A very high GA loading capacity (3:10 drug/polymer w/w) and sustained drug release were achieved with the optimized telodendrimers. These novel nanoformulations of GA were found to exhibit similar in vitro cytotoxic activity against colon cancer cells as the free drug. Near-infrared fluorescence small animal imaging revealed preferential accumulation of GA-loaded NPs into tumor tissue. The optimized nanoformulation of GA achieved superior antitumor efficacy compared to GA-Cremophor EL formulation at equivalent doses in HT-29 human colon cancer xenograft mouse models. Given the mild adverse effects associated with this natural compound and the enhanced anticancer effects via tumor targeted telodendrimer delivery, the optimized GA nanoformulation is a promising alternative to the traditional chemotherapy in colon cancer treatment.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorColonic NeoplasmsDendrimersDrug CarriersDrug Delivery SystemsDrug DesignFemaleHCT116 CellsHemolysisHumansLightMCF-7 CellsMiceMicellesAntineoplastic AgentsDendrimersDrug Carriersgambogic acidMicellesPolyethylene GlycolsVitamin EXanthonescolon cancer therapydrug deliverymacromolecular architecturenanoparticlesnatural anticancer reagents

Identifiers

PMID25692376
PMCPMC8214075
OpenAlexW2000295370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.